Tempus AI Investors Sell 1,500 Jan 2027 Puts at $8.35 for $41.65 Entry
Tempus AI shares traded at $51.40 on March 3 with a trailing P/E of 39.3 as investors highlight the company’s expanding clinical and molecular database powering AI-driven oncology insights. Investors sold 1,500 January 2027 $50 put contracts at $8.35, targeting a $41.65 entry to capture long-term compounding upside.
1. Thesis Overview
Tempus AI is presented as a long-term growth opportunity at the intersection of oncology, data compounding and artificial intelligence, with a focus on building the world’s largest clinical and molecular dataset to enhance drug discovery insights.
2. Put Selling Strategy
The sale of 1,500 January 2027 $50 put contracts at $8.35 establishes an effective entry price of $41.65, allowing investors to collect premium and limit downside exposure while positioning for future upside.
3. Data Flywheel Mechanism
As more oncologists utilize Tempus’s sequencing services, the dataset expands and AI-driven insights improve, boosting platform value to pharmaceutical partners and reinforcing a self-reinforcing growth cycle.
4. Risk Profile and Outlook
Despite ongoing high cash burn and regulatory uncertainties, the disciplined use of options ensures ownership only at attractive risk-reward levels, underpinning a generational healthcare AI asset thesis spanning oncology, pathology and cardiology.